Loading market dashboard
Hansa Biopharma AB (publ)
HNSA.STHealthcareSTOSE
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ STOCKHOLM: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
/PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter